Bluestar Genomics appoints David Mullarkey to its Board of Directors as CEO alongside Dr. Samuel Levy remaining as CSO

– USA, CA –  Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced the appointment of David Mullarkey to its board of directors as CEO, effective January 10, succeeding acting CEO and CSO, Dr. Samuel Levy who will continue as CSO.

David Mullarkey brings an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings.

“Dave is a terrific addition to the Bluestar Genomics executive team as the company transitions to becoming a commercial organization and brings its non-invasive cancer detection technology to patients. He brings proven expertise as a leader in the genomics industry and health care more broadly, and I know that Sam is looking forward to returning his full focus to the company’s science,” said Dr. Stephen Quake, co-founder of Bluestar Genomics and Board member.

About David Mullarkey

Most recently, David Mullarkey was president and CEO of Omniome, where he raised over $150 million and guided the DNA sequencing company from the early technology development through the delivery of a beta prototype leading to its sale to Pacific Biosciences in 2021. Before Omniome, Mullarkey served as the president and COO of Ariosa Diagnostics, driving rapid global revenue growth and market development for the cell-free DNA non-invasive prenatal testing company resulting in the acquisition by Roche in 2014. Post-acquisition, Mullarkey led the integration of the Ariosa business and served as a global lifecycle leader, site head for a 250-person CLIA Lab/R&D location, and a core member of the Roche Sequencing Solutions leadership team. He has also held leadership positions at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceutical Sciences.

“The Bluestar Genomics platform is demonstrating unsurpassed performance in identifying some of the deadliest cancers at very early stages of disthe ease. Having received FDA breakthrough device designation for early detection of pancreatic cancer, the team is focused on expediting the generation of high-quality, rigorous clinical data and making the test available for patients,” said Dave Mullarkey, incoming CEO. “Having the opportunity to push the boundaries of science, work as part of an incredibly talented and driven team, and most importantly aggressively pursue lifesaving innovations is both humbling and rewarding.”

About Bluestar Genomics

Bluestar Genomics is an early cancer detection company focused on the development and commercialization of non-invasive epigenomic tests to detect cancer through a standard blood draw, earlier than existing methods and when the disease is still treatable. The company uses its one-of-a-kind epigenomic platform that combines best-in-class bioinformatics and genomic technologies to analyze individuals’ changing biology that is yet to produce symptoms. Leveraging its novel liquid biopsy technology, Bluestar Genomics is initially focused on high-mortality cancers with the greatest need for early detection, starting with pancreatic and women’s cancers. With locations in San Diego and the San Francisco Bay Area, Bluestar Genomics collaborates with top research institutions and is supported by multiple global healthcare and technology investors and pharmaceutical collaborations.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.